logo
ALIMENTATION COUCHE-TARD REINITIATES SHARE REPURCHASE PROGRAM USA - English USA - English USA

ALIMENTATION COUCHE-TARD REINITIATES SHARE REPURCHASE PROGRAM USA - English USA - English USA

Cision Canada5 days ago
LAVAL, QC, July 21, 2025 /CNW/ - Alimentation Couche-Tard Inc. (" Couche‑Tard") (TSX: ATD) announced today that the Toronto Stock Exchange (" TSX") has approved the share repurchase program (the " Program"), authorizing Couche‑Tard to repurchase up to 77,115,921 Common Shares (the " Shares"), representing 10% of the 771,159,210 Shares comprising Couche-Tard's "public float" (as such term is defined in the TSX Company Manual) as at July 14, 2025. Based on the current share price the completion of the Program in full would represent a total investment of approximately US $4.2 billion or CDN $5.8 billion. As at July 14, 2025, there were 948,064,405 Shares issued and outstanding.
The average daily trading volume for the six-month period preceding June 30, 2025 represents 1,316,554 Shares. In accordance with TSX requirements, Couche-Tard is entitled to purchase, on any trading day, up to a total of 329,138 Shares representing 25% of this average daily trading volume.
Couche-Tard believes that the purchase of up to 77,115,921 Shares under the Program is an appropriate use of its funds and a desirable investment for Couche-Tard and, therefore, would be in the best interests of Couche-Tard. By making such repurchases, the number of Shares in circulation will be reduced and the proportionate interest of all remaining shareholders in the share capital of Couche-Tard will be increased on a pro rata basis.
"With a strong balance sheet and confidence in our long-term strategy, we believe this program represents an efficient way to create long-term shareholder value," said Filipe Da Silva, Chief Financial Officer.
Under the terms of the Program, Couche-Tard may repurchase up to 77,115,921 Shares on the open market through the facilities of the TSX and through alternative trading systems in Canada, as well as outside the facilities of the TSX pursuant to exemption orders issued by securities regulators, over the course of twelve months commencing July 23, 2025 and ending at the latest on July 22, 2026. All Shares will be purchased at their market price at the time of acquisition, except for purchases effected outside the facilities of the TSX pursuant to exemption orders issued by securities regulators which will be at a discount to the market price as provided in such exemption orders.
The actual number of Shares purchased under the Program, the timing of purchases and the price at which the Shares are bought will depend upon management discretion based on factors such as market conditions. All Shares repurchased under the Program will be cancelled upon their repurchase.
Under Couche-Tard's previous Program which commenced on May 1, 2024 and expired on April 30, 2025, Couche-Tard obtained approval from the TSX to repurchase for cancellation up to 78,083,521 Shares. During the past 12 months, Couche-Tard repurchased 8,695,652 Shares outside the facilities of TSX by way of private agreement in reliance upon a decision obtained from the Autorité des marchés financiers to exempt the issuer from issuer bid requirements under applicable securities legislation, and such Shares were acquired at a price of CAD $80.50 per Share.
In connection with the Program, Couche-Tard has established an automatic share purchase plan ("ASPP") with a designated broker whereby Shares may be repurchased at times when such purchases would otherwise be prohibited pursuant to regulatory restrictions or self-imposed blackout periods. Under the ASPP, before entering a self-imposed blackout period, Couche-Tard may, but is not required to, ask the designated broker to make purchases under the Program. Such purchases will be made at the discretion of the designated broker, within parameters established by Couche-Tard prior to the blackout periods. Outside the blackout periods, purchases will be made at the discretion of Couche-Tard's management. The ASPP will constitute an "automatic plan" for purposes of applicable Canadian securities legislation and has been pre-cleared by the TSX.
About Alimentation Couche-Tard Inc.
Couche-Tard is a global leader in convenience and mobility, operating in 29 countries and territories, with close to 17,000 stores, of which approximately 13,000 offer road transportation fuel. With its well-known Couche-Tard and Circle K banners, it is one of the largest independent convenience store operators in the United States and it is a leader in the convenience store industry and road transportation fuel retail in Canada, Scandinavia, the Baltics, Belgium, as well as in Ireland. It also has an important presence in Luxembourg, Germany, the Netherlands, Poland, as well as in Hong Kong Special Administrative Region of the People's Republic of China. Approximately 146,000 people are employed throughout its network.
For more information on Alimentation Couche-Tard Inc., or to consult its audited annual Consolidated Financial Statements, and Management Discussion and Analysis, please visit: https://corpo.couche-tard.com.
Forward-Looking Statements
This press release may include certain statements that are "forward-looking information" within the meaning of the securities laws of Canada, including statements relating to the Program. Any statement in this press release that is not a statement of historical fact may be deemed to be forward-looking information. When used on this press release, the words "believe", "could", "should", "intend", "expect", "estimate", "assume", "aim", "align", "maintain", "continue", "effect", "growth", "position", "seek", "strategy", "strive", "will", "may", "might" and other similar expressions or the negative of these terms are generally intended to identify forward-looking information, although not all forward-looking statements include such words. These statements are based on management's current expectations, assumptions and estimates, which it believes are reasonable, but which are subject to a number of risks and uncertainties that could cause actual results and outcomes to differ materially, including risks associated with market and economic conditions, future plans and projections, and regulatory trends and changes, and such other risks as described in detail from time to time in documents filed by Couche-Tard with securities regulatory authorities in Canada. All forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement and speak as of the date of this news release. Couche-Tard undertakes no obligation to publicly update such forward-looking information to reflect new information, subsequent or otherwise, unless required by applicable securities laws.
SOURCE Alimentation Couche-Tard Inc.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca's New Trial: A Potential Game-Changer in Prostate Cancer Treatment
AstraZeneca's New Trial: A Potential Game-Changer in Prostate Cancer Treatment

Globe and Mail

time23 minutes ago

  • Globe and Mail

AstraZeneca's New Trial: A Potential Game-Changer in Prostate Cancer Treatment

AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase I clinical trial titled A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer. The study aims to assess the safety and tolerability of the drugs AZD2284, AZD2287, and AZD2275 in treating this aggressive form of prostate cancer. The trial is testing three drugs: AZD2284, AZD2287, and AZD2275, all administered via intravenous methods. AZD2284 is the primary focus, with the goal of determining its optimal dosing and efficacy in conjunction with the other two drugs. This non-randomized, open-label study follows a sequential intervention model. It is primarily focused on treatment, with no masking involved, allowing for direct observation of the drug effects. The study began on March 10, 2025, with the latest update submitted on July 22, 2025. These dates are crucial as they indicate the study's progress and the timeline for potential results. This study's update could influence AstraZeneca's stock performance positively, as successful results may enhance investor confidence and market position in the oncology sector. Competitors in the prostate cancer treatment market will be closely monitoring these developments. The study is currently recruiting, with further details available on the ClinicalTrials portal.

AstraZeneca's AZD0486 Study: A Potential Game-Changer in B-Cell Lymphoma Treatment
AstraZeneca's AZD0486 Study: A Potential Game-Changer in B-Cell Lymphoma Treatment

Globe and Mail

time23 minutes ago

  • Globe and Mail

AstraZeneca's AZD0486 Study: A Potential Game-Changer in B-Cell Lymphoma Treatment

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca is conducting a phase 1 clinical study titled A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma. The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AZD0486 in patients with B-cell non-Hodgkin lymphoma. The intervention being tested is AZD0486, a bispecific antibody designed to engage T-cells and target CD19 on tumor cells, facilitating T cell-mediated destruction of malignant B cells. It is administered intravenously in a structured dosing schedule. This interventional study follows a sequential intervention model with no masking, focusing primarily on treatment. Participants receive increasing doses of AZD0486, with safety and efficacy monitored throughout the study. The study began on March 2, 2021, and is currently recruiting. The last update was submitted on July 22, 2025. These dates are crucial for tracking the study's progress and ensuring timely updates to stakeholders. The ongoing study may influence AstraZeneca's stock performance and investor sentiment, as successful outcomes could enhance the company's oncology portfolio. Investors should also consider the competitive landscape in the B-cell lymphoma treatment market. The study is ongoing, with further details available on the ClinicalTrials portal.

AstraZeneca's Latest Study: Evaluating Ceralasertib's Impact on Cancer Drug Pharmacokinetics
AstraZeneca's Latest Study: Evaluating Ceralasertib's Impact on Cancer Drug Pharmacokinetics

Globe and Mail

timean hour ago

  • Globe and Mail

AstraZeneca's Latest Study: Evaluating Ceralasertib's Impact on Cancer Drug Pharmacokinetics

AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase I clinical study titled 'A Phase I, Open-label, Fixed-sequence Study to Evaluate the Effect of Ceralasertib on Pharmacokinetics of Drug X, Drug Y and Drug Z in Participants With Advanced Solid Tumours.' The study aims to assess how ceralasertib affects the pharmacokinetics of three other drugs in patients with advanced solid tumors, potentially offering new insights into cancer treatment. The intervention involves administering ceralasertib, alongside Drugs X, Y, and Z. Ceralasertib is given twice daily over a week, with single doses of the other drugs administered on specific days to evaluate interactions. This open-label study follows a single-group assignment model with no masking, focusing on treatment as its primary purpose. It includes multiple visits and wash-out periods to ensure accurate results. The study began on May 21, 2025, with the latest update submitted on July 22, 2025. These dates are crucial for tracking the study's progress and ensuring transparency. For investors, this study could influence AstraZeneca's stock performance by potentially expanding its oncology portfolio. The collaboration with Parexel highlights a strategic partnership that could enhance research capabilities, impacting investor sentiment positively. Competitors in the oncology sector may also be closely monitoring these developments. The study is currently recruiting, with further details available on the ClinicalTrials portal.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store